Actym Therapeutics utilizes its STACT™ platform, an engineered S. Typhimurium bacterial delivery system, to locally produce and amplify therapeutic payloads for the treatment of cancer and fibrotic diseases. This approach minimizes systemic toxicity associated with traditional therapeutic administration methods while enhancing treatment efficacy at the disease site.
Funding
$59.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BIFounders
Product
Problem
Systemic administration of cancer and fibrosis therapeutics often leads to significant toxicity, limiting the dosage and effectiveness of the treatment. Traditional methods struggle to deliver sufficient therapeutic payloads directly to the disease site while minimizing harm to healthy tissues.
Solution
Actym Therapeutics utilizes its STACT™ (S. Typhimurium Anti-Cancer Therapy) platform, an engineered bacterial delivery system, to overcome the limitations of traditional therapeutic administration. The STACT™ platform employs a modified strain of S. Typhimurium to selectively target and colonize tumors and fibrotic tissues. Once at the disease site, the bacteria locally produce and amplify therapeutic payloads, enhancing treatment efficacy while minimizing systemic toxicity. This targeted approach allows for higher concentrations of the therapeutic agent to reach the affected area, potentially leading to improved patient outcomes.
Target Audience
The primary target audience includes patients with advanced solid tumors and fibrotic diseases, as well as oncologists and researchers seeking more effective and less toxic treatment options.
Features
- Engineered S. Typhimurium strain for targeted delivery to tumors and fibrotic tissues
- Local production and amplification of therapeutic payloads at the disease site
- Minimized systemic toxicity compared to traditional administration methods
- Potential for higher therapeutic concentrations at the target site
- ACTM-838: Lead program currently in Phase 1 clinical trials for advanced solid tumors